FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

| OMB APPROVAL | | | | | | | | |
|--------------------------|-----------|--|--|--|--|--|--|--|
| OMB Number: | 3235-0287 | | | | | | | |
| Estimated average burden | | | | | | | | |
| hours per response | e: 0.5 | | | | | | | |

| | Check this box if no longer subjec |
|--------|------------------------------------|
| \neg | to Section 16. Form 4 or Form 5 |
| _ | obligations may continue. See |
| | Instruction 1(b). |

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| Name and Address of Reporting Person* Gallagher Cam | | | | 2. Issuer Name and Ticker or Trading Symbol Zentalis Pharmaceuticals, Inc. [ZNTL] | | | | | | | | | | | all app Direc | | ng Pe | 10% O | wner | |
|---|--|--------------------------------------|--|--|--|---|------------------------|-------|--|--------|--|--|---------------------|------------|--|---|--|--|--|---------|
| (Last) | , | First) (Middle) HARMACEUTICALS, INC. | | | | 3. Date of Earliest Transaction (Month/Day/Year) 05/31/2023 | | | | | | | | | | Officer (give title below) | | Other (below) | | specify |
| 1359 BROADWAY, SUITE 801 | | | | 4. If | 4. If Amendment, Date of Original Filed (Month/Day/Year) | | | | | | | | | | 6. Individual or Joint/Group Filing (Check Applicable Line) | | | | | |
| (Street) NEW Y | ORK N | Y 1 | 10018 | | | | | | | | | | | | | Form filed by One Reporting Person Form filed by More than One Reporting Person | | | | |
| (City) (State) (Zip) | | | | | Ru | Rule 10b5-1(c) Transaction Indication | | | | | | | | | | | | | | |
| | | | | | X | | | | | | | nsaction was nditions of R | | | | | struction or w | ritten p | olan that is ir | itended |
| | | Table | I - I | Non-Deriva | tive | Secu | ritie | s Ac | cqui | red, C | Dis | posed o | f, or | Benefi | cially | Owr | ned | | | |
| Date | | | 2. Transaction Date (Month/Day/Yea | 2A. Deem Execution if any (Month/D | | on Dat | n Date, | | 3. Transaction Code (Instr. 8) | | 4. Securities Acquired (A) of Disposed Of (D) (Instr. 3, 4 | | | d 5) | 5. Amount of Securities Beneficially Owned Following | | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |
| | | | | | | | | | Code | v | Ai | mount | (A) or (D) Price | | | Reported Transaction(s) (Instr. 3 and 4) | | | | |
| Common Stock | | | | 05/31/2023 | 3 | | | | S ⁽¹⁾ | | | 9,242 | D | D \$26.398 | | 089 482,028 | | D | | |
| Common Stock | | | | 05/31/2023 | 3 | | | | | | | 18,526 | D | \$26.20 |)79 ⁽³⁾ | 463,502 | | | D | |
| | | Tab | ole | II - Derivativ (e.g., pu | | | | | | | | | | | | Owne | ed | | | |
| 1. Title of Derivative Security (Instr. 3) | vative Conversion Date urity or Exercise (Month/Day/Year) Execution Date, if any | | | 4. Trans Code 8) | | of Der Sec Acc (A) Dis of (| posed D) str. 3, | e s l | 6. Date Exercisable and Expiration Date (Month/Day/Year) Date Expiration Exercisable Date | | | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4 and 4 and 5 and 6 and | | nt er | | | | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | |

Explanation of Responses:

- 1. The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units.
- 2. The sale reported in this Form 4 was effected pursuant to a plan that complies with Rule 10b5-1 and expires June 5, 2023.
- 3. The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from \$25.91 to \$26.51. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

/s/ Melissa B. Epperly,
Attorney-in-Fact for Cam S. 05/31/2023
Gallagher

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.